Modern-day stenting procedures leverage advances in pharmacotherapy and device
innovation. Patients treated with contemporary antiplatelet agents, peri-procedural …

Since the first coronary angioplasty on Sept 16, 1977, the field of percutaneous coronary
intervention has evolved rapidly. Now marking its 40th anniversary, percutaneous coronary …

Background The risk of stroke varies considerably across different groups of patients with
atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is associated with an increased …

Background Despite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR)
may still occur in as many as 2–10% of percutaneous coronary interventions (PCI) in certain …

Background Balloon-expandable coronary-artery stents were developed to prevent coronary
restenosis after coronary angioplasty. These devices hold coronary vessels open at sites …

Background This guideline focuses on long-term administration of antithrombotic drugs
designed for primary and secondary prevention of cardiovascular disease, including two …

Background Antithrombotic drugs are used after coronary-artery stenting to prevent stent
thrombosis. We compared the efficacy and safety of three antithrombotic-drug regimens …

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the world.
Central to the pathogenesis of CAD is the development of atherosclerotic lesions in coronary …

Coronary artery stents revolutionized the practice of interventional cardiology after they were
first introduced in the mid-1980s. Since then, there have been significant developments in …

Restenosis is a reparative response to arterial injury occurring with percutaneous coronary
revascularization. However, the quantitative characteristics of the relation between vessel …